



aTyr Pharma

aTyr Pharma to Present at Upcoming May Investor Conferences

April 29, 2016

SAN DIEGO, April 29, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation in two upcoming investor conferences. John Mendlein, Ph.D., aTyr's CEO, will provide an overview of the Company during the following presentations:

- **Deutsche Bank 41st Annual Health Care Conference:** Wednesday, May 4, 2016 at 12:50 p.m. ET at the InterContinental Hotel in Boston, MA
- **Bank of America Merrill Lynch 2016 Health Care Conference:** Wednesday, May 11, 2016 at 5:00 p.m. PT (8:00pm ET) at the Encore at Wynn Las Vegas in Las Vegas, NV



aTyr Pharma

The presentations will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr built an intellectual property estate comprising over 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit <http://www.atyrpharma.com>.

Contacts:

Mark Johnson
Senior Director, Investor Relations
mjohnson@atyrpharma.com
858-875-1101

Jesse Baumgartner
Stern Investor Relations, Inc.
jesse@sternir.com
212-362-1200

Logo - <http://photos.prnewswire.com/prnh/20120809/MM555381LOGO>

SOURCE aTyr Pharma, Inc.